Without this credential, businesses risk losing access to a rare four-year debt restructuring window that allows qualifying firms to postpone installment payments for up to two years and subsequently amortize the balance over an additional two-year period.
The administrative pathway requires careful coordination between multiple government bodies. Securing the Biopyme certification is only the initial step and does not automatically freeze active payment obligations, as warned by Alberto Velasco, technical secretary of the Register of Forensic Economists (Refor). Businesses must file a secondary application with the local Delegation of Economy and Finance during the voluntary payment window of each specific installment. Treasury officials review these filings individually to verify that the liquidity crunch is temporary, apply statutory late-payment interest, and determine whether to grant both the requested payment schedule and a waiver of guarantees.
To qualify for the program, corporate entities must satisfy strict operational and financial criteria. Sole proprietors operating as natural persons are entirely excluded from the procedure. Eligible firms must operate within strict European Union small-and-medium enterprise thresholds, maintaining fewer than 250 employees, an annual turnover under a maximum of 50 million euros annually, or a general balance sheet totaling a maximum of 43 million euros. Furthermore, applicants must prove an intense commitment to research and development by demonstrating that at least 30 percent of their operating expenses—excluding depreciation and financial costs—were dedicated to R&D and technological innovation during one of the three preceding fiscal years.
Independent verification is mandatory for compliance. Applicants must submit a formal report signed by an auditor registered in the Official Registry of Account Auditors to validate the investment percentage. Additionally, companies must provide a comprehensive viability plan demonstrating that cash flow pressures are short-term and that the core business model remains robust enough to generate sufficient future revenue to fully repay the capital.
Eligibility and Exclusions Under State Loan Programs
The special deferral mechanism applies exclusively to public, non-tax, and non-customs debt originating from ten specific state-sponsored R&D loan convocations. Commercial bank loans, private credit arrangements, unpaid corporate taxes, and public debts outside the designated programs are strictly excluded from the relief framework.
Firms that miss the September application window or fail to properly coordinate their filings with the Ministry of Science, Innovation and Universities and the Ministry of Finance face standard debt collection procedures. While the Ministry of Science maintains a three-month window to process Biopyme certificate requests, submitting the application alone does not halt the accrual of default interest or protect the debt from entering executive collection phases if the voluntary payment period lapses without a formal Treasury deferral request.
Frequently Asked Questions
What happens if the Ministry of Science does not resolve the Biopyme certificate request before the voluntary payment period ends?
If the official certificate remains pending, companies should submit proof of having requested the document alongside their Treasury deferral application.
Does obtaining the Biopyme certificate completely eliminate the need for loan guarantees?
No, the waiver of guarantees is not automatic. The Treasury evaluates each case individually based on demonstrated temporary liquidity issues and the feasibility of the proposed repayment schedule. Existing collateral tied to prior loan convocations must be formally reviewed and adjusted through the General Deposit Box as appropriate.
Are self-employed individuals eligible for this debt restructuring program?
No, the framework is restricted strictly to formal corporate entities engaged in economic market activities, explicitly barring independent freelancers operating as natural persons from utilizing the Biopyme pathway.
Worth a look